LGG Probiotic Sachets: Evidence by Condition and Age

Lactobacillus rhamnosus GG, or LGG, is the most studied probiotic strain in the world, with guideline support for preventing antibiotic-associated diarrhoea in children and for shortening acute gastroenteritis. Its evidence for respiratory infections and eczema prevention is promising but less certain, and it has no proven role in many other claims. A sachet is a convenient powder form for families, provided the dose and the person are matched to what trials tested.

This guide sets out the evidence for LGG condition by condition, explains how sachet doses relate to trial doses, and describes how to use and judge a LGG sachet.

What is LGG?

LGG is a strain of Lacticaseibacillus rhamnosus, formerly Lactobacillus rhamnosus, isolated in 1983 from the intestine of a healthy adult by the researchers Sherwood Gorbach and Barry Goldin, whose initials give the strain its name. It is held in culture collections as ATCC 53103.

The strain was selected for its ability to survive stomach acid and bile, to attach to intestinal cells and to grow well in production. It has since been the subject of well over a thousand scientific publications, covering laboratory work and trials in infants, children, adults and older people.

The strain code matters. Many L. rhamnosus strains exist, and results for LGG cannot be assumed for them. A sachet should state "LGG" or "ATCC 53103" if it is to be linked to this research. The mechanism of attachment is described in LGG pili and mucus binding: how the strain attaches.

How does LGG act in the gut?

Mechanisms proposed from laboratory and animal work include:

Attachment. LGG carries hair-like surface structures called pili, which bind mucus and help the bacteria stay in the gut longer than non-adherent strains.

Barrier support. In cell and animal models, LGG strengthens the tight junctions between gut lining cells and increases mucus production.

Competition. It competes with some pathogens for binding sites and produces lactic acid that lowers local pH.

Immune interaction. Components of the LGG cell surface interact with immune receptors and influence cytokine signalling in gut tissue.

Secreted proteins . Two proteins released by LGG, p40 and p75, protected gut cells from injury in laboratory models.

These findings explain plausibility. They are not proof that a given dose improves a specific condition in a particular person.

Where is the evidence strongest?

Acute gastroenteritis in children

Acute watery diarrhoea is where LGG has the best-known evidence. The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) suggests LGG as an addition to rehydration in children with acute gastroenteritis, with the recommendation graded as weak and the evidence as low to very low certainty. The typical benefit in trials is a shorter duration of diarrhoea, by about one day on average.

Oral rehydration solution remains the cornerstone of treatment, and zinc is advised for children in many settings. A probiotic is an adjunct. The topic is covered for children in ELMED's article on LGG for acute diarrhoea in children.

Prevention of antibiotic-associated diarrhoea in children

In 2016, an ESPGHAN working group strongly recommended LGG, together with Saccharomyces boulardii, for preventing antibiotic-associated diarrhoea (AAD) in children receiving antibiotics, with a moderate quality of evidence. Pooling five randomised trials with 445 children, LGG lowered the risk of AAD from about 23 percent to 9.6 percent, a relative risk of 0.48. About eight children needed to be treated to prevent one case.

The working group noted that the best dose is unclear, with the largest effect in one trial at 10 to 20 billion CFU per day. It did not find that LGG prevented Clostridioides difficile infection, and the one trial available showed no effect. Details are in LGG and antibiotic-associated diarrhoea in children.

Where is the evidence promising but less certain?

Respiratory infections in childcare

A randomised, double-blind trial in Zagreb, Croatia, gave 281 children in day care either fermented milk containing 1 billion CFU of LGG or the same milk without LGG for three months over winter. LGG reduced the risk of upper respiratory tract infections and of infections lasting more than three days, and reduced the number of days with respiratory symptoms. It did not reduce lower respiratory infections or gastrointestinal infections. Authors noted that diagnoses relied on clinical judgement and that the study did not cover summer. The study is examined in LGG and respiratory infections in day care children.

Findings across other trials are mixed, so this is a possible benefit, not an established one.

Eczema prevention

A Finnish randomised trial gave LGG to pregnant women at high risk of allergy in the weeks before delivery, and then to the mother or infant for six months after birth. The incidence of atopic eczema at two years was about half that of placebo, and the benefit persisted at four years, with children about 40 percent less likely to have eczema. There was no protective effect for asthma or allergic rhinitis in follow-up.

Other trials and reviews have been less consistent, and allergy guidelines give only cautious support to probiotics for eczema prevention, if any. The Finnish trials are covered in LGG and eczema prevention: what the Finnish trials show.

Where is the evidence limited or mixed?

Adults. LGG has been studied in adults for traveller's diarrhoea, antibiotic-associated diarrhoea and irritable bowel syndrome, with results that differ between trials. No major guideline recommends LGG for a specific adult digestive disorder.

Functional abdominal pain in children. Small paediatric trials of LGG have reported fewer pain episodes in some children, particularly with irritable bowel syndrome, but results are inconsistent and reviews rate the certainty as low.

Colic. For infant colic, Limosilactobacillus reuteri DSM 17938 has the more consistent evidence. LGG has not shown reliable benefit.

Clostridioides difficile. LGG has not been shown to prevent it.

General immunity. Claims that LGG boosts immunity in general are not supported by trial evidence beyond the respiratory findings above.

How does the strength of evidence compare across uses?

A short summary helps place each use on a scale. The ratings below describe the certainty of evidence as reported by guideline groups and reviews, not the size of benefit.

Prevention of antibiotic-associated diarrhoea in children. Strong recommendation, moderate-quality evidence (ESPGHAN 2016).

Shortening acute gastroenteritis in children. Weak recommendation, low to very low certainty (ESPGHAN 2020).

Respiratory infections in day care. Promising, from single trials, with low certainty overall in pooled reviews.

Eczema prevention in high-risk infants. Conditional suggestion in some guidelines, very low certainty, with inconsistent replication.

Adult digestive conditions. Mixed, with no guideline endorsement.

Prevention of C. difficile infection. No evidence of benefit for LGG.

This ladder matters because the same strain is sometimes marketed with claims that outrun the evidence. A parent or clinician who knows where the strong evidence sits can ask for the product to be used for that purpose.

How long should LGG be taken?

For acute diarrhoea, trials gave LGG for a few days to a week, and benefit if any appeared within that time. For prevention of antibiotic-associated diarrhoea, the probiotic was given through the antibiotic course and sometimes for a short time after. For respiratory infection prevention, the Croatian trial gave LGG for three months. For eczema prevention, the Finnish trial ran from late pregnancy to six months after birth.

For general support without a clear target, a defined trial of two to four weeks with a symptom record is reasonable. Continuing indefinitely without a purpose has no evidence behind it.

Is there a difference between LGG and S. boulardii?

Both are well supported for preventing antibiotic-associated diarrhoea in children. LGG is a bacterium. S. boulardii is a yeast and is not killed by antibacterial antibiotics, which may be an advantage during treatment, but it should be avoided in people with central venous catheters or severe immune compromise because of rare fungal bloodstream infections. LGG is generally preferred in infants for practical reasons and has the broader paediatric record. Choice is usually made by the clinician.

What special groups need extra thought?

Pregnancy and breastfeeding. LGG has been used in trials in healthy pregnant and breastfeeding women without safety concerns. Women with medical conditions should check with their doctor.

Older adults. Evidence for LGG in older adults is limited, and people in hospital or long-term care with frailty, catheters or feeding tubes need medical guidance.

Children with chronic illness. Children with cancer, transplants, severe malnutrition or inflammatory bowel disease should use probiotics only under specialist advice.

Travellers. Evidence that LGG prevents traveller's diarrhoea is mixed. Food and water safety, handwashing and oral rehydration remain the main protections.

What common myths surround LGG?

"LGG is a medicine for diarrhoea." It is a probiotic adjunct that may shorten diarrhoea by about a day in children, not a replacement for rehydration.

"More CFU means a stronger effect." No consistent dose-response holds across uses.

"Probiotics rebuild the whole microbiome." LGG is a temporary visitor and does not usually colonise permanently.

"Probiotics are harmless for everyone." They are safe for most, but not for every vulnerable person.

"Any lactobacillus will do." Effects are strain-specific, and LGG evidence cannot be borrowed for other strains.

How do diet and hygiene interact with a probiotic?

A probiotic works alongside the basics, not in place of them. For a child with diarrhoea, continuing age-appropriate food, giving oral rehydration solution and washing hands are the central measures. For adults, fibre diversity, regular meals and sleep matter. For infants, breastfeeding supports a healthy early microbiome. Safe water and food handling prevent many infections in the first place.

How does a sachet dose relate to trial doses?

Trials of LGG have used amounts from about 1 billion to 20 billion CFU a day, in capsules, fermented milk, powders and drops. The respiratory trial used 1 billion CFU, while the pooled AAD analyses found the largest effect at 10 to 20 billion CFU per day.

A sachet of 6 billion CFU is within the range studied. The daily number of sachets and the duration depend on the reason for use and should follow the product label and a doctor's advice. Trial results describe the strain and a dose range, and they do not guarantee the same effect from any product.

What are the LGG sachets from ELMED?

Rhamnosus GG Sachets from ELMED Life Sciences contain Lactobacillus rhamnosus GG (ATCC 53103 ) at 6 billion CFU per sachet, with an 18-month shelf life. ELMED describes them as paediatric-friendly from infancy. They sit alongside Rhambac GG Drops, which provide LGG ATCC 53103 as drops.

The choice between formats depends on age, preference and dose flexibility. The comparison is in LGG sachets, drops or capsules: choosing a format.

This is a nutraceutical supplement intended to support gut balance and is not a treatment for any disease.

How should a sachet be given?

Empty the sachet into a small amount of cool or room-temperature water, milk, curd or soft food, stir and give it straight away. Avoid hot foods and drinks. For babies, mix the powder into a few millilitres of expressed breast milk or cooled boiled water and give it by spoon or oral syringe. Make sure the entire portion is taken. Store sachets sealed, in a cool, dry place, and follow the label.

If a child or adult is taking an antibiotic, space the doses by two to three hours, and ask the prescribing doctor. For diarrhoea, give oral rehydration solution first and as the main treatment.

What can families expect after starting a sachet?

For acute diarrhoea, any benefit is usually a shorter illness by a day or so, not an instant stop. For antibiotic-associated diarrhoea, the aim is fewer or milder loose stools during the course. Some children have a little extra wind in the first days. Stool pattern, appetite, fluid intake and energy are the things to watch, and a child who is getting worse needs a doctor, not a higher dose.

Is LGG safe?

LGG has a strong safety record. Large trials in infants, children and adults have found mild effects only, such as wind or loose stools. Rare cases of bloodstream infection with LGG have been reported, almost always in people with serious underlying illness, central venous catheters or very low immunity, and surveillance data from countries with high LGG consumption have not shown an increase in such infections.

Take medical advice before using LGG if the person:

• is a premature or very low birth weight infant
• has a weakened immune system or is receiving chemotherapy
• has a central venous catheter
• has a damaged heart valve
• is critically ill or recently had major abdominal surgery
• has short bowel syndrome

Regulatory agencies have warned about probiotics in preterm infants in neonatal units, where infections from probiotic organisms have occurred. The neonatal team, not parents, should make that decision.

When should a doctor be consulted?

Seek medical care for a baby under three months with fever, for blood in the stool, repeated vomiting, signs of dehydration (dry mouth, very few wet nappies, sunken eyes, unusual drowsiness), high fever, severe abdominal pain, diarrhoea lasting more than a few days, or poor weight gain. Adults should seek care for weight loss, anaemia, night-time symptoms, black stools or new bowel changes after age 50.

How can you judge the quality of an LGG sachet?

Look for the strain code, CFU per sachet guaranteed until expiry, a list of all other ingredients, moisture-protective packaging, clear mixing and storage instructions, batch number and expiry date, and manufacture in a GMP Certified facility. Avoid products that claim to cure or treat disease.

Key takeaways

• LGG is the best-studied probiotic strain, with strong guideline support for preventing antibiotic-associated diarrhoea in children and a weak recommendation for shortening acute gastroenteritis.
• Respiratory infection and eczema findings are promising but less consistent, and other claims lack firm support.
• A 6 billion CFU sachet falls within the range used in trials, but dose and duration should follow the label and medical advice.
• Rehydration, not a probiotic, is the first treatment for diarrhoea.
• Preterm infants, immunocompromised people and those with central lines need a doctor's guidance first.